AtlasCancersNeoplasms

Thyroid cancer

4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251998 — Thyrotropin alfa approved (FDA)2005 — Sorafenib approved (FDA)2011 — Vandetanib approved (FDA)2012 — Cabozantinib approved (FDA)2015 — Lenvatinib approved (FDA)2020 — Selpercatinib approved (FDA)
1998: Drug approval — Thyrotropin alfa approved (FDA). 2005: Drug approval — Sorafenib approved (FDA). 2011: Drug approval — Vandetanib approved (FDA). 2012: Drug approval — Cabozantinib approved (FDA). 2015: Drug approval — Lenvatinib approved (FDA). 2020: Drug approval — Selpercatinib approved (FDA)

What's being tested now

2000: 1 trials started2005: 1 trials started2009: 3 trials started2010: 2 trials started2011: 2 trials started2012: 2 trials started2013: 2 trials started2014: 2 trials started2015: 3 trials started2016: 4 trials started2017: 6 trials started2018: 6 trials started2019: 7 trials started2020: 11 trials started2021: 9 trials started2022: 22 trials started2023: 23 trials started2024: 46 trials started2025: 65 trials started2026: 41 trials started200020102020202665

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 241 active Papillary Thyroid Cancer trials on Clin2 →

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.